SCHEMBL5879196

SCHEMBL5879196

Cn1c(=O)c2c3[nH]c4ccccc4c3c3c(=O)oc(=O)c3c2c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.50
ADORA3 P0DMS8 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA2B P29275 1/20 0.46
ADORA1 P30542 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
POLB P06746 1/20 0.45
PPARG P37231 1/20 0.45
RAB9A P51151 1/20 0.45
NCOA2 Q15596 1/20 0.45
NCOA1 Q15788 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ROCK2 O75116 3/20 0.44
CDK4 P11802 2/20 0.43
CCND1 P24385 2/20 0.43
PRKCA P17252 3/20 0.42
CDK5 Q00535 4/20 0.42
CDK5R1 Q15078 3/20 0.42
DYRK1A Q13627 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879218 0.97 CHEK1 (0.50) CHEK1ADORA3ADORA2AADORA2BADORA1
SCHEMBL5879141 0.91 CHEK1 (0.59) CHEK1ADORA3ADORA2AADORA2BADORA1
SCHEMBL5879158 0.85 CHEK1 (0.71) CHEK1ADORA3ADORA2AADORA2BADORA1
SCHEMBL5879155 0.84 CHEK1 (0.51) CHEK1ADORA3ADORA2AADORA2BADORA1
SCHEMBL5879140 0.84 CHEK1 (0.51) CHEK1ADORA3ADORA2AADORA2BADORA1
SCHEMBL5879135 0.82 CHEK1 (0.76) CHEK1ADORA3ADORA2AADORA2BADORA1
SCHEMBL5879307 0.82 CHEK1 (0.49) CHEK1ADORA3ADORA2AADORA2BADORA1
SCHEMBL5337910 0.80 MAP3K11 (0.46) CHEK1ADORA3ADORA2AADORA2BADORA1
SCHEMBL5879415 0.79 CHEK1 (0.75) CHEK1MEN1KMT2APOLBPPARG
SCHEMBL5879183 0.78 ALDH1A1 (0.56) CHEK1ADORA3ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CHEK1 943/4885ADORA3 2648/4885ADORA2A 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.